Lexaria Bioscience Q4 2023 Earnings Report

Lexaria Bioscience EPS Results

• Actual EPS: -$0.12
• Consensus EPS: -$0.17
• Beat/Miss: Beat by +$0.05
• One Year Ago EPS: N/A

Lexaria Bioscience Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Lexaria Bioscience Announcement Details

• Quarter: Q4 2023
• Date: 11/21/2023
• Time: N/A

Lexaria Bioscience (NASDAQ:LEXX) operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.